pharmaphorum

JANUARY 5, 2022

The year 2020 ended on a note of hope, with the 8th December vaccination of 91-year-old Margaret Keenan, the world’s first person to receive a COVID-19 vaccine outside clinical trials. Add to this the fact that the world missed the WHO targets for global vaccination by the end of 2021 and will likely continue to miss targets in 2022.

HIV Treatment and Prevention Agents 98

HIV Treatment and Prevention Agents Vaccines FDA 98

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face. Launch opportunity is reduced.

HIV Treatment and Prevention Agents 59

HIV Treatment and Prevention Agents Vaccines Pharmaceutical Companies Pharmaceutical Companies 59

Druggist

SEPTEMBER 2, 2021

Experts believe that this medicine can be highly effective against parasites present inside and outside the body. With an ongoing vaccination program globally, experts hope that a large world population will soon get a vaccine that protects against corona. And stated its judicial use in preventing corona infection.

HIV Treatment and Prevention Agents 52

HIV Treatment and Prevention Agents Adverse Reactions Hospitals FDA 52

PharmaShots

APRIL 25, 2023

This year Roche has secured the top position with a total R&D Expenditure of $15.20B, followed by Johnson & Johnson and AstraZeneca PharmaShots presents the Top 20 RNAi therapeutic companies based on their R&D Expenditure in the year 2022 R&D Expenditure: $43.1M R&D Expenditure: $85.1M R&D Expenditure: $437.9M

HIV Treatment and Prevention Agents 40

HIV Treatment and Prevention Agents Packaging Immunization Vaccines 40